BioGenex

🔬 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬 𝐟𝐨𝐫 𝐏𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲 𝐋𝐚𝐛𝐬! 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐗𝐦𝐚𝐭𝐫𝐱® 𝐈𝐧𝐟𝐢𝐧𝐢𝐭𝐲 Are you ready to revolutionize your Cellular & Molecular Pathology Lab? We're thrilled to introduce Xmatrx® Infinity, the most advanced and fully automated system designed to supercharge your life sciences research, drug discovery, and development processes. 🚀 𝐊𝐞𝐲 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐬 & 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬: 🌟 Fully Automated: Streamline your lab with 40 simultaneous assays. 🧪 Multi-Format Compatibility: Works with various specimen types. 🌡️ Precise and Consistent: eXACT™ Temperature Control, precise dispensing. 🌐 Open System: Adaptable to any slide-based staining assay. 💲 Cost-Efficient: Minimal reagent usage (as low as 10µL). Ready to revolutionize your lab? Learn More: https://hubs.la/Q02Vh00f0 #PathologyLab #labautomation #XmatrxInfinity

🔬 Understanding B-Cell Malignancies with BOB1 🔬 B-cell-specific Octamer Binding protein-1 (BOB1) plays a critical role as a co-activator of OCT-2 and is essential for antigen-dependent germinal center formation. BOB1 is an invaluable tool in differentiating malignancies of B cell origin, particularly in diagnosing B-cell lymphoma. 💡 Why BOB1 Matters: Dysregulated BOB1 expression contributes to the development of B-cell lymphoma. Lack of BOB1 expression helps distinguish between lymphocyte predominance Hodgkin lymphoma (LPHL) and classic Hodgkin lymphoma (CHL). Strong association with Epstein-Barr virus (EBV) positivity enhances diagnostic accuracy. At BioGenex, we offer ready-to-use (RTU) and concentrated forms of BOB1 antibodies for both manual and automated systems, providing pathologists and clinicians with the precision they need for clinicopathological diagnosis and drug discovery. 🔗 Learn more about our best-in-class solutions: BioGenex #BCellLymphoma #BOB1Antibody #CancerDiagnostics #PathologySolutions #BioGenex #Immunohistochemistry #CancerResearch

🌸 October is Breast Cancer Awareness Month 🌸 At BioGenex, we are proud to support the fight against breast cancer with our comprehensive panel of Breast Cancer Antibodies. These high-quality antibodies are designed to enhance diagnostic accuracy and help medical professionals detect and treat breast cancer earlier and more effectively. 🔬 Our Breast Cancer Antibodies include: Estrogen Receptor (ER) Progesterone Receptor (PR) HER2/neu Ki-67 p53 And more! With the right tools, we can make a difference in the early detection and treatment of breast cancer. Let’s work together to save lives. 🌟 Visit BioGenex to learn more about our Breast Cancer Antibodies panel. #BreastCancerAwareness #BreastCancerResearch #PathologySolutions #CancerDiagnostics #BioGenex #Immunohistochemistry #CancerAntibodies

🔬 BioGenex Introduces Anti-HLA-DR/DP/DQ/DX Antibody for Lymphocytic Tumor Diagnosis 🧬 The Anti-HLA-DR/DP/DQ/DX antibody is a critical tool in the diagnosis of lymphocytic tumors, targeting the MHC Class II cell surface receptor. These molecules play a key role in immune response by presenting processed peptides to T-helper cells, essential for identifying infections and cancerous cells. Key Features: MHC Class II antibodies expressed on antigen-presenting cells like B lymphocytes, macrophages, and activated T cells. Available in ready-to-use (RTU) and concentrated forms for both manual and automated systems. Ideal for clinicopathological diagnosis and drug discovery, enhancing precision in cancer diagnostics. BioGenex’s antibodies are designed to empower pathologists and clinicians to improve diagnostic accuracy and patient outcomes. Learn More: https://hubs.la/Q02R-lK80 Learn more about how our cutting-edge solutions can support your lab! #Immunology #LymphomaDiagnosis #Pathology #CancerResearch #HealthcareInnovation #DrugDiscovery #MHCClassII #BioGenex

Boost your pathology lab's capabilities with BioGenex i6000™ Diagnostics! 𝑯𝒆𝒓𝒆 𝒂𝒓𝒆 𝒔𝒐𝒎𝒆 𝒌𝒆𝒚 𝒇𝒆𝒂𝒕𝒖𝒓𝒆𝒔 𝒂𝒏𝒅 𝒃𝒆𝒏𝒆𝒇𝒊𝒕𝒔: 𝐇𝐢𝐠𝐡 𝐓𝐡𝐫𝐨𝐮𝐠𝐡𝐩𝐮𝐭: Process up to 200 slides in an 8-hour shift, enhancing productivity. 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐓𝐲𝐩𝐞𝐬: From frozen to formalin-fixed paraffin-embedded (FFPE) samples, cell preparations, and smears, it handles them all. 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐞𝐝 𝐏𝐫𝐨𝐭𝐨𝐜𝐨𝐥𝐬: Over 600 pre-optimized staining protocols ensure consistent and reliable results. 𝐏𝐫𝐞𝐜𝐢𝐬𝐞 𝐑𝐞𝐚𝐠𝐞𝐧𝐭 𝐃𝐢𝐬𝐩𝐞𝐧𝐬𝐢𝐧𝐠: Minimize wastage with dispensing as low as 100 µL per slide, ensuring cost-effectiveness. 𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐭 𝐖𝐨𝐫𝐤𝐟𝐥𝐨𝐰: Streamline processes with minimal hands-on time, improving overall efficiency. 𝐀𝐜𝐜𝐮𝐫𝐚𝐭𝐞 𝐑𝐞𝐚𝐠𝐞𝐧𝐭 𝐇𝐚𝐧𝐝𝐥𝐢𝐧𝐠: Liquid level sensor ensures precise management, reducing errors. 𝐓𝐡𝐢𝐫𝐝-𝐏𝐚𝐫𝐭𝐲 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 𝐂𝐨𝐦𝐩𝐚𝐭𝐢𝐛𝐢𝐥𝐢𝐭𝐲: Flexibility in staining options with compatibility for third-party antibodies. 𝐒𝐩𝐚𝐜𝐞-𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐭 𝐃𝐞𝐬𝐢𝐠𝐧: Occupies about 70% less space compared to other systems, without compromising throughput. 𝐁𝐚𝐫𝐜𝐨𝐝𝐞𝐝 𝐑𝐞𝐚𝐠𝐞𝐧𝐭 𝐕𝐢𝐚𝐥𝐬: Simplify workflow with ready-to-use barcoded vials, minimizing technician time. 𝐒𝐞𝐚𝐦𝐥𝐞𝐬𝐬 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧: Works seamlessly with EZ–Retriever® IR System and i500 barcode printer for efficient de-waxing, rehydration, and antigen retrieval. Unlock the potential of your pathology lab with BioGenex i6000™ Diagnostics. Contact us for more information!" Learn more: https://hubs.la/Q02RDd9q0

📢 BioGenex Launches Anti-p40 Antibody for Prostate Cancer Diagnosis! 🧬 Our Anti-p40 antibody, specific to the delta-Np63 isoform, helps differentiate prostate adenocarcinoma from benign glands and distinguishes between types of breast cancer. It’s also effective in identifying squamous cell carcinomas. Available in ready-to-use (RTU) and concentrated formats, BioGenex antibodies ensure precise diagnosis and improved patient outcomes. Learn More: https://hubs.la/Q02Rct9N0 #ProstateCancer #BreastCancer #Pathology #CancerDiagnosis #BioGenex #Healthcare

🔬 We're excited to share some highlights from our participation in the NSH 2024 tradeshow from September 20–24 in New orleans, LA! BioGenex had a fantastic time connecting with industry professionals, showcasing our innovative solutions, and learning about the latest advancements in the field. Swipe through to see some of our favorite moments from the event. 👉 Know More: https://lnkd.in/dhC-yKee #NSH2024 #BioGenex #Pathology #Innovation #Tradeshow Avijit Paul, PhD Satya Kalra

🌟 Highlights from the 7th Annual Conference of the Indian Association of Pathologists & Microbiologists (Telangana State Chapter) 2024! 🌟 On September 14-15, we joined leading experts at Osmania Medical College, Hyderabad, for insightful discussions on the latest advancements in pathology and microbiology. Key moments included: Engaging keynote speeches Interactive panels Valuable networking opportunities Thank you to the organizers and participants for an inspiring event! Excited to implement our learnings and look forward to the next edition! 💡🔬 #IAPM2024 #Pathology #Microbiology #Networking #Innovation

🚀 Meet NanoVIP® 100 – Simplifying Pathology with Precision Automation! The NanoVIP® 100 streamlines complex FISH, ISH, miRNA ISH, and IHC protocols, reducing a 33-step manual process to just 3 simple steps: load, click, view. With advanced automation, precise liquid handling, and the ability to run 10 protocols simultaneously, it's the ideal choice for clinical labs. 🔗 Learn more: https://lnkd.in/dP_pjAG2 #NanoVIP100 #DigitalPathology #PrecisionBiology #HealthcareTechnology #Biogenex

Companion Diagnostics Market $13.6 Billion by 2029 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dtttEEfB The global size of companion diagnostics market in terms of revenue was estimated to be worth $7.5 billion in 2024 and is poised to reach $13.6 billion by 2029, growing at a CAGR of 12.6% from 2024 to 2029 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Roche Agilent Technologies QIAGEN Thermo Fisher Scientific Abbott Danaher Corporation Guardant Health Illumina bioMérieux ICON plc Myriad Genetics Sysmex Corporation Almac Group ARUP Laboratories Abnova BioGenex Invivoscribe Q² Solutions Amoy Diagnostics Unigen Corporation Asuragen MESO SCALE DIAGNOSTICS, LLC. Creative Biolabs NG BIOTECH